Next Generation Antibody Therapies Market Forecast 2016-2026

LONDON, May 11, 2016 /PRNewswire/ --

- Explore Developments and Sales Potentials for ADCs, Engineered Antibodies, ALPs, Bispecific and Biosimilar Agents 

- Next-Generation Antibody Therapies - Your 2016 Guide to Trends, R&D and Predicted Revenues

Where are next generation antibody therapies heading? Visiongain's new report shows you potential revenues to 2026, giving R&D trends, opportunities and sales forecasting.

Discover in our study the most promising and lucrative parts of that industry. Our analysis lets you assess forecasted sales at overall world market, submarket, product and regional level. That work shows you results, interviews, trends and opportunities.
 
Many opportunities remain in that expanding market for new biological drugs. Discover what its future holds, with the following sections explaining how our study can help your work.

Forecasts from 2016-2026 and other analyses show you revenue potentials
Besides revenue forecasting to 2026, our new study shows you recent results, growth rates, and market shares. There you find original analyses exploring developments and business outlooks.

In our report you get 87 tables and 46 charts explaining that market. See what its future holds and the potential gains. Find data to benefit your plans, decisions and proposals.

There you also discover qualitative analyses (including SWOT and STEP analysis), product profiles and commercial developments. You also find our interviews with three companies - Ablynx, arGEN-X and Mersana Therapeutics - giving insight to help you stay ahead.

Sales predictions for the world market and submarkets - see what is possible
Along with revenue prediction for the overall world market, our study shows you revenue forecasts to 2026 for the following five submarkets:
• Antibody-drug conjugates (ADCs)
• Engineered antibodies
• Bispecific antibodies

To see a report overview please email Sara Peerun on [email protected]

• Antibody fragments and antibody-like proteins (ALPs)
• Biosimilar antibody therapies.

That investigation discusses what stimulates and restrains business. There discover what is possible for monoclonal antibodies and other agents. You find dynamics of the industry and assess its sales potentials, exploring treatments giving high commercial opportunities.

Leading next-generation therapeutic antibodies - what are their prospects?
How will leading next-generation antibody therapies perform to 2026 at world level? Our study forecasts individual revenues of seven products, showing you what revenues are possible:
• Adcetris
• Kadcyla
• Gazyva/Gazyvaro
• Poteligeo
• Removab
• Blincyto
• Kalbitor.

Discover how high those sales can go. With our study you see what is happening, exploring trends, challenges and opportunities.

Our analysis also breaks its main world forecast into geographical submarkets.

Leading regions - assess prospects for next-generation antibody sales
In addition to analyses of the overall world market, our study lets you explore individual revenue forecasts to 2026 for four regional markets:
• US
• EU5 group
• Asia-Pacific region
• Latin America
• Rest of the World.

With that analysis you see where the highest and fastest expanding revenues can occur. That industry holds great potential for opportunities and rising sales. Discover what is possible.

Potential for market growth - how much expansion possible by 2020?
Our study predicts high revenue growth from 2016 to 2026. Launches of novel therapies, investments from international pharmaceutical companies and increasing demand for treatments for serious chronic diseases will increase those agents' sales from 2016 to 2026.

Our analysis forecasts that the worldwide next-generation antibodies market will generate $11.6 billion in 2020. There discover capabilities, progress, and commercial prospects, helping you stay ahead in knowledge and benefit your reputation for commercial insight.

Research and development - assess innovation, trends and possibilities
What about R&D - the pipeline for new drugs? Our report explains, covering these fields:
• Antibody-drug conjugates (ADCs)
• Engineered antibodies
• Bispecific antibodies
• Antibody fragments and antibody-like proteins (ALPs)
• Other progress in next-generation antibody development.

Our study also discusses these agents and technologies, among others:
• Site-specific linkers
• Glycosylation or glycoengineering
• Defucosylation
• Amino acid modification
• Enhanced antibody-dependent cell-mediated cytotoxicity (ADCC)
• Bispecific, trispecific and multi-specific antibodies
• Domain fragments
• Single-chain variable fragments
• Alternative scaffolds: DARPins, anticalins, Affibodies, Fynomers, Affilins, Adnectins and i-bodies
• Combination therapies.

R&D is particularly strong for antibody-drug conjugates. Also novel products and biobetters with high safety, efficacy and affordability are in great demand. Our work explains, discussing many issues to help your work.

Issues affecting the next-generation antibody therapies industry from 2016
Our survey discusses forces affecting those companies. There you find discussions of these and other issues:
• Approved products indicating a path to regulatory and market acceptance
• R&D for next generation antibodies - explore technologies and potentials
• Challenges with current monoclonal antibody (mAb) therapies
• Big pharma companies investing in next-generation antibody research and development
• Biosimilars and their effects on the market for those next-generation biologics.

That investigation explains social, technological, economic and political forces, with emphasis on competition and business outlooks. Assess what drives and restrains developers, producers and marketers of those emerging biologic medicines.

7 ways Next-Generation Antibody Therapies Market Forecast 2016-2026 helps you
In these seven main ways, our new report helps your research, analysis, plans, decisions and presentations:
• Revenue forecasts to 2026 for the world next-generation antibody therapies market and 5 segments - discover that industry's prospects, seeing its sales potentials
• Predicted revenues to 2026 for the leading 4 regional markets - assess sales outlooks in the US, EU5, Asia-Pacific and Latin America
• Sales potentials of 7 leading drugs to 2026 - see how high products' revenues can go
• Review of R&D - investigate trends and progress, seeing what is possible, finding the most promising developments
• Discussion of what stimulates and restrains leading companies - explore strengths, weaknesses, opportunities and threats, assessing that industry's prospects
• Outlooks for established competitors and new market entrants - hear what scope exists for companies to increase their business and compete from 2016
• Interviews from our survey, showing views from 3 companies - gain insight from that industry to help your work.

There you gain competitive intelligence found only in our analysis, finding sales potentials. Benefit your influence by exploring commercial progress, opportunities and potentials.

Trying our new study now lets you discover antibody trends, opportunities and forecasts
With our new report, by visiongain's UK-based in-house analysts, you discover analysis to help you stay ahead in knowledge. See there what the future holds for developers, producers and sellers of therapeutic antibodies. Find data you get nowhere else.

Our investigation is for everyone analysing biopharmaceuticals. There you discover data and forecasts for new antibody-based drugs. Avoid missing out and falling behind in knowledge. Instead please get our new report here now.

To see a report overview please email Sara Peerun on [email protected]

To request an exec summary of this report please email Sara Peerun at [email protected] or call Tel: +44 (0) 20 7336 6100

Or click on https://www.visiongain.com/Report/1632/Next-Generation-Antibody-Therapies-Market-Forecast-2016-2026

Organisations Mentioned in the Report 

AbbVie

Ablynx

AdAlta

ADC Therapeutics

Affimed Therapeutics

Agensys

Alcon

Alexion

Allergan

Ambrx

American Society of Clinical Oncology Genitourinary Cancers (ASCO GU) Symposium

American Society of Hematology

Amgen

arGEN-X

Astellas Pharma

AstraZeneca

Bayer

Biogen Idec

BioNet Ventures

Biotest

BioWa

Boehringer Ingelheim

Bristol-Myers Squibb

Cancer Drugs Fund

Catalent Pharma Solutions

Celgene

Celldex Therapeutics

Cephalon

Cilag GmbH International

Coldstream Laboratories

Concortis Biosystems

Corixa

Covagen

Crescendo Biologics

CSL Behring

CVie Therapeutics

Daiichi Sankyo

Defiante Farmaceutica

Delenex Therapeutics

Domantis

Dutalys

Dyax

Eddingpharm

Eisai

Eli Lilly

ESBATech

FDA

Five Prime Therapeutics

Fresenius Biotech

F-Star

Fujifilm

Genentech

Genmab

Gilead Sciences

Glenmark

Glycotope

Goodwin Biotechnology

GSK

Igenica

Immunocore

ImmunoGen

Immunomedics

Janssen Biotech

Kalobios

Karolinska Institute

Kyowa Hakko Kirin

Kyowa Medex

LINDIS Biotech

Lonza

MacroGenics

MedImmune

Merck  

Merrimack Pharmaceuticals

Mersana Therapeutics

Merus

Micromet

Millennium Pharmaceuticals

Molecular Partners

MorphoSys

MultiCell Immunotherapeutics (MCIT)

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Neopharm

Neovii Biotech

NHS

NICE

Novartis

Novartis Institutes for BioMedical Research (NIBR)

NovImmune

Oxford BioTherapeutics

Oxis

Pfizer

Pharmacyclics

Piarmal Healthcare

Pieris

Piramal Enterprises

PolyTherics

Progenics

ProStrakan

Redwood BioScience

Roche

Salix

Sanofi

Scil Proteins

Seattle Genetics

Servier

Shinogi

Shire

Sigma-Tau

Sorrento Therapeutics

Spectrum Pharmaceuticals

Spirogen

Stelis Biopharma

Strides Arcolab

Sutro Biopharma

Swedish Orphan Biovitrum (Sobi)

Swiss Federal Institute of Technology

Synthon

Takeda

Talon Therapeutics

Teva

TG Therapeutics

TRION Pharma

UCB

WHO

Wyeth

Xencor

Zydus Cadila

To see a report overview please email Sara Peerun on [email protected]

SOURCE Visiongain Ltd